Small Caps Begin to Rebound: 5 Stocks to Buy Now

Page 1 of 5

In this article, we discuss 5 rebounding small-cap stocks to buy now. If you want to see more stocks in this category, check out Small Caps Begin to Rebound: 10 Stocks to Buy Now

5. 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Number of Hedge Fund Holders: 11

Market Capitalization as of August 11: $337.856 million

1-month Share Price Gain as of August 11: 31.24%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a California-based clinical-stage gene therapy company, developing a portfolio of gene therapy products in three segments – ophthalmology, cardiology, and pulmonology. The stock has rebounded 31.24% in the last month as of August 11. 

Jefferies analyst Nalin Tejavibulya on June 22 initiated coverage of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) with a ‘Buy’ rating and $22 price target. The company offers a “potentially differentiated” gene therapy platform with a pipeline that has five assets in Phase 1/2 testing across three key therapeutic areas, the analyst told investors. Incremental updates over the upcoming 12 to 24 months could reinforce platform differentiation and the analyst sees the risk/reward ratio as being “highly attractive” given the large application of its potential treatments.

According to Insider Monkey’s data, 11 hedge funds were long 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) at the end of the first quarter of 2022, compared to 13 funds in the previous quarter. Andreas Halvorsen’s Viking Global is the leading position holder in the company, with 3.9 million shares worth $59.5 million. 

Page 1 of 5